APAC / Medtech's Post-COVID Paradigm
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine…
The latest news from Middle East & North African pharma, including Pfizer’s transformation of its Saudi…
With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected…
As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last…
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness…
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and…
Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights…
One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they…
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…